Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intermittent treatment with Apremilast, a phosphodiesterase-4 inhibitor, ameliorates Alzheimer's-like pathology and symptoms through multiple targeting actions in aged T2D rats
Adel A. Gomaa, Hanan S.M. Farghaly, Asmaa M. Ahmed, et al.
International Immunopharmacology (2023) Vol. 117, pp. 109927-109927
Closed Access | Times Cited: 9

Showing 9 citing articles:

Connecting dots: Preclinical foundations to clinical realities of PDE4 inhibitors in Alzheimer's disease
Shilpa Kumari, Kajal Bagri, Rahul Deshmukh
Inflammopharmacology (2025)
Closed Access | Times Cited: 2
Cyclic nucleotide phosphodiesterases as drug targets
Michy P. Kelly, Viacheslav O. Nikolaev, Leila Gobejishvili, et al.
Pharmacological Reviews (2025) Vol. 77, Iss. 3, pp. 100042-100042
Open Access | Times Cited: 1
Drug repositioning based on mutual information for the treatment of Alzheimer’s disease patients
Claudia Cava, Isabella Castiglioni
Medical & Biological Engineering & Computing (2025)
Closed Access
Correlation of autophagy and Alzheimer's disease with special emphasis on the role of phosphodiesterase-4
Aniruddha Banerjee, Dithu Thekkekkara, S Manjula, et al.
3 Biotech (2025) Vol. 15, Iss. 5
Closed Access
PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE
Phool Chandra, Vikas Sharma
INDIAN DRUGS (2024) Vol. 61, Iss. 07, pp. 7-22
Closed Access | Times Cited: 3
Identification of vilazodone as a novel plasminogen activator inhibitor to overcome Alzheimer's disease through virtual screening, molecular dynamics simulation, and biological evaluation
Wenxiu Sun, Xuan Sheng, Peiru Li, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 9
Closed Access | Times Cited: 1
Adipocyte-Derived Small Extracellular Vesicles from Patients with Alzheimer Disease Carry miRNAs Predicted to Target the CREB Signaling Pathway in Neurons
Rachael Batabyal, Ankush Bansal, Laura Reck Cechinel, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 14024-14024
Open Access | Times Cited: 3
Cardioprotective Effects of Phlorizin on Hyperlipidemia-induced Myocardial Injury: Involvement of Suppression in Pyroptosis via Regulating HK1/NLRP3/Caspase-1 Signaling Pathway
Yuling Zhang, Yanan Wang, Xizhen Cheng, et al.
Applied Biochemistry and Biotechnology (2024)
Closed Access
Natural and Synthetic Phosphodiesterase Inhibitors in 2023: an Update on the Impact on Neurological and Psychiatric Conditions
Giovanni Ribaudo, Alessandra Gianoncelli
Mini-Reviews in Medicinal Chemistry (2023) Vol. 24, Iss. 6, pp. 568-570
Closed Access
Page 1

Scroll to top